EMA Adopts a New Pharmaceutical Form of Selumetinib By Ogkologos - December 16, 2025 344 0 Facebook Twitter Google+ Pinterest WhatsApp It is associated with an extension to the existing indication Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Findings support de-escalated radiotherapy after surgery in HPV-associated oropharyngeal squamous cell... September 23, 2025 Gilteritinib Improves Survival in AML with FLT3 Mutations November 27, 2019 Woman Discovers Breast Lump in the Shower After Dropping Her Loofah,... November 3, 2020 Delayed irAEs Occur in a Small Subset of Patients with Melanoma,... April 1, 2021 Load more HOT NEWS Young Woman’s Breast Cancer Diagnosis Ends Up Saving Her Mom’s Life... Tattoo Artist Offers Free Nipple Tattoos To Breast Cancer Patients That... Should People with Cancer and Cancer Survivors Get the Flu Vaccine? Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast...
